- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05541081
Investigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe (IPSAZ)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sexually transmitted infections (STIs) can cause serious morbidity including pelvic inflammatory disease, infertility, poor mental health, adverse pregnancy outcomes and an increased risk of HIV transmission. In low and middle-income countries (LMICs), STIs are treated using syndromic management, which has poor sensitivity and specificity, leading to considerable levels of both underdiagnosis and overtreatment. In recent years, simpler diagnostic platforms for STIs have been developed. Development and evaluation of strategies for provision of diagnostic testing in LMICs are needed and the World Health Organization (WHO) has called for evidence to inform replacement of syndromic management by diagnostic testing.
The aim of this project is to evaluate a strategy of point-of-care (POC) testing for STIs including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe.
The objectives are to:
- Determine the uptake, prevalence and yield of chlamydia, gonorrhoea, trichomoniasis, syphilis and hepatitis B testing, and risk factors for infection among women attending for antenatal care
- Assess the acceptability and feasibility of this intervention
- Estimate the cost and cost-effectiveness of POC STI testing
- Investigate the prevalence of antimicrobial resistance for Neisseria gonorrhoeae to inform the development of a gonococcal antimicrobial resistance surveillance programme
- Assess an incentives-based approach to optimize uptake of client-referral partner notification.
A prospective interventional study will be conducted in three primary healthcare clinics (PHCs) in Harare province, Zimbabwe. 1000 pregnant women will be recruited over a nine month period when registering for routine antenatal care. Testing will be staggered across sites so that testing will be available at each site for three months within the nine-month study period. All Identified STIs will be managed comprehensively including treatment and/or referral if required according to national guidelines, and partner notification and risk reduction counselling.
Given the relatively low number of gonococcal isolates likely to be obtained from pregnant women alone, men attending the PHCs with urethral discharge will be recruited to gain sufficient numbers to establish a surveillance programme. Urethral samples will be collected from 140 men with urethral discharge, to support the assessment of antimicrobial resistance amongst patients with gonorrhoea.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kevin Martin, MBBS
- Phone Number: +263774410908
- Email: kevin.martin@lshtm.ac.uk
Study Locations
-
-
-
Harare, Zimbabwe
- Mbare polyclinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Pregnant woman
- Attending a study site for antenatal care
Exclusion criteria:
- Enrolment in this study on a previous antenatal visit
- Unable to provide consent in English or Shona
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Point-of-care STI testing
Provision of point-of-care testing for chlamydia, gonorrhoea, trichomoniasis, syphilis, HIV, and hepatitis B, with comprehensive case management including partner notification
|
Testing for:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite STI prevalence
Time Frame: Through study completion, up to 1 year
|
Composite % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and/or hepatitis B
|
Through study completion, up to 1 year
|
Individual STI prevalences
Time Frame: Through study completion, up to 1 year
|
Individual % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and hepatitis B
|
Through study completion, up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uptake of STI testing
Time Frame: Through study completion, up to 1 year
|
% of individuals approached who accept and undergo testing
|
Through study completion, up to 1 year
|
Yield of STI testing
Time Frame: Through study completion, up to 1 year
|
% of individuals approached who test positive for an STI
|
Through study completion, up to 1 year
|
Uptake of treatment
Time Frame: Through study completion, up to 1 year
|
% of participants with a curable STI who accept treatment
|
Through study completion, up to 1 year
|
Uptake of partner notification
Time Frame: Through study completion, up to 1 year
|
% of participants with a curable STI who undertake partner notification
|
Through study completion, up to 1 year
|
Prevalence of antimicrobial resistance in gonococcal isolates
Time Frame: Through study completion, up to 1 year
|
% of gonococcal isolates with resistance to ceftriaxone, cefixime, azithromycin, and ciprofloxacin
|
Through study completion, up to 1 year
|
Prevalence of adverse birth outcomes
Time Frame: Through study completion, up to 2 years
|
% of pregnancies with premature birth, miscarriage, or low birth weight
|
Through study completion, up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kevin Martin, MBBS, London School of Hygiene and Tropical Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Parasitic Diseases
- Protozoan Infections
- Neisseriaceae Infections
- Hepatitis
- Sexually Transmitted Diseases, Bacterial
- Spirochaetales Infections
- Treponemal Infections
- Urogenital Diseases
- Genital Diseases
- Infections
- Communicable Diseases
- Hepatitis B
- Gonorrhea
- Sexually Transmitted Diseases
- Syphilis
- Trichomonas Infections
Other Study ID Numbers
- 26787
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Point-of-care STI testing
-
Centre for the AIDS Programme of Research in South...Johns Hopkins University; National Institute of Allergy and Infectious Diseases...CompletedSexually Transmitted Diseases | HIV PreventionSouth Africa
-
Kirby InstituteRecruiting
-
KU LeuvenTerminated
-
University of CincinnatiMayo Clinic; University of Pennsylvania; Stanford University; Abbott; Jewish Hospital...CompletedAngina, UnstableUnited States
-
University of California, San FranciscoUS Department of Veterans Affairs; Agency for Healthcare Research and Quality...CompletedCoughUnited States
-
Kettering Health NetworkBilimetrix s.r.l.RecruitingKernicterus | Point-of-Care Testing | Neonatal Screening | Newborn JaundiceUnited States
-
University of StellenboschCompletedTuberculosisSouth Africa
-
Fundacion para la Investigacion Biomedica del Hospital...Completed
-
Imperial College LondonSense Biodetection LimitedUnknownEnterovirus Infections | Respiratory Syncytial Virus Infections | Human Influenza | Rhinoviral Infections | Metapneumovirus Infection | Parainfluenzae Viral InfectionsUnited Kingdom
-
The Aurum Institute NPCLondon School of Hygiene and Tropical Medicine; Johns Hopkins University; United... and other collaboratorsCompleted